NeurologyLive Friday 5 — February 21, 2020
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 21, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Lower Adherence Linked to Higher Out of Pocket Costs in Neurologic Disorders
"These data confirm the need for consideration of these costs when prescribing treatments, and is of considerable importance as out of pocket costs continue to rise in the US.
2: Aducanumab Reinvigorates the Fight Against Alzheimer Disease
The chief medical officer of ProMIS Neurosciences comments on how aducanumab will help propel innovation needed to drive the next generation of therapies for Alzheimer disease.
3: Amantadine Successful in Reducing Dyskinesia: Clinical Takeaways
The vice president of Medical Affairs at Adamas Pharmaceuticals discussed the context of these results and what the clinical community should take away from the data from the EASE LID 2 trial of amantadine (Gocovri).
4: Amit Bar-Or, MD, FRCP: Next Steps in Treating Progressive MS
The multiple sclerosis expert at the University of Pennsylvania detailed the gaps in treatment for progressive multiple sclerosis and some of the different mechanisms being explored.
5: Risk Score May Help Identify Migraine Patients At Risk for Stroke
The model may help clinicians enact preventative measures for those with migraine with aura at an early stage.
